Truist raised the firm’s price target on Bristol Myers (BMY) to $65 from $62 and keeps a Buy rating on the shares as part of a broader research ...
Bristol-Myers Squibb has rebounded strongly in 2024, driven by key drug approvals and positive financial performance. See why ...
Short BMY slightly under 59.95, target 53.71, stop loss @ 60.12 Check the time stamp on this data. Updated AI-Generated ...
Medtronic (NYSE: MDT), Bristol Myers Squibb (NYSE: BMY), and AbbVie (NYSE: ABBV) have many years of reliable dividend growth under their belts.
The final trades of the day with CNBC’s Melissa Lee and the Fast Money traders. The first migrant caravan of the year has set ...
The increases are to list prices, which do not include rebates to pharmacy benefit managers and other discounts.
Below is Validea's guru fundamental report for BRISTOL-MYERS SQUIBB CO (BMY). Of the 22 guru strategies we follow, BMY rates highest using our Multi-Factor Investor model based on the published ...
Bristol Myers Squibb (NYSE:BMY) said it expects to report a Q4 net expense of $18M related to acquired IPRD and licensing ...